These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 38762829)
1. Enhancing Temozolomide (TMZ) chemosensitivity using CRISPR-dCas9-mediated downregulation of O Yousefi Y; Nejati R; Eslahi A; Alizadeh F; Farrokhi S; Asoodeh A; Mojarrad M J Neurooncol; 2024 Aug; 169(1):129-135. PubMed ID: 38762829 [TBL] [Abstract][Full Text] [Related]
2. dCas9/CRISPR-based methylation of O-6-methylguanine-DNA methyltransferase enhances chemosensitivity to temozolomide in malignant glioma. Zapanta Rinonos S; Li T; Pianka ST; Prins TJ; Eldred BSC; Kevan BM; Liau LM; Nghiemphu PL; Cloughesy TF; Lai A J Neurooncol; 2024 Jan; 166(1):129-142. PubMed ID: 38224404 [TBL] [Abstract][Full Text] [Related]
3. Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells. Taspinar M; Ilgaz S; Ozdemir M; Ozkan T; Oztuna D; Canpinar H; Rey JA; Sunguroğlu A; Castresana JS; Ugur HC Tumour Biol; 2013 Jun; 34(3):1935-47. PubMed ID: 23519841 [TBL] [Abstract][Full Text] [Related]
4. Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status. Wu Q; Berglund AE; Macaulay RJ; Etame AB Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894860 [TBL] [Abstract][Full Text] [Related]
5. AP-2α decreases TMZ resistance of recurrent GBM by downregulating MGMT expression and improving DNA damage. Huang G; Ouyang M; Xiao K; Zhou H; Zhong Z; Long S; Li Z; Zhang Y; Li L; Xiang S; Ding X Life Sci; 2024 Nov; 357():123111. PubMed ID: 39369843 [TBL] [Abstract][Full Text] [Related]
6. SNAP reverses temozolomide resistance in human glioblastoma multiforme cells through down-regulation of MGMT. Tsai CK; Huang LC; Wu YP; Kan IY; Hueng DY FASEB J; 2019 Dec; 33(12):14171-14184. PubMed ID: 31725331 [TBL] [Abstract][Full Text] [Related]
7. Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines. Lombardi F; Augello FR; Artone S; Gugu MK; Cifone MG; Cinque B; Palumbo P Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163465 [TBL] [Abstract][Full Text] [Related]
8. Circadian regulation of MGMT expression and promoter methylation underlies daily rhythms in TMZ sensitivity in glioblastoma. Gonzalez-Aponte MF; Damato AR; Trebucq LL; Simon T; Cárdenas-García SP; Cho K; Patti GJ; Golombek DA; Chiesa JJ; Rubin JB; Herzog ED J Neurooncol; 2024 Feb; 166(3):419-430. PubMed ID: 38277015 [TBL] [Abstract][Full Text] [Related]
9. PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma. Wu S; Li X; Gao F; de Groot JF; Koul D; Yung WKA Neuro Oncol; 2021 Jun; 23(6):920-931. PubMed ID: 33433610 [TBL] [Abstract][Full Text] [Related]
10. Pharmacological inhibition of serine synthesis enhances temozolomide efficacy by decreasing O Jin L; Kiang KM; Cheng SY; Leung GK Lab Invest; 2022 Feb; 102(2):194-203. PubMed ID: 34625658 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model. Kitange GJ; Carlson BL; Mladek AC; Decker PA; Schroeder MA; Wu W; Grogan PT; Giannini C; Ballman KV; Buckner JC; James CD; Sarkaria JN J Neurooncol; 2009 Mar; 92(1):23-31. PubMed ID: 19011762 [TBL] [Abstract][Full Text] [Related]
12. Dynamic structural remodeling of LINC01956 enhances temozolomide resistance in Liao X; Zhang S; Li X; Qian W; Li M; Chen S; Wu X; Yu X; Li Z; Tang M; Xu Y; Yu R; Zhang Q; Wu G; Zhang N; Song L; Li J Sci Transl Med; 2024 Oct; 16(767):eado1573. PubMed ID: 39356744 [TBL] [Abstract][Full Text] [Related]
13. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression. Perazzoli G; Prados J; Ortiz R; Caba O; Cabeza L; Berdasco M; Gónzalez B; Melguizo C PLoS One; 2015; 10(10):e0140131. PubMed ID: 26447477 [TBL] [Abstract][Full Text] [Related]
14. A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma. Chen X; Zhang M; Gan H; Wang H; Lee JH; Fang D; Kitange GJ; He L; Hu Z; Parney IF; Meyer FB; Giannini C; Sarkaria JN; Zhang Z Nat Commun; 2018 Jul; 9(1):2949. PubMed ID: 30054476 [TBL] [Abstract][Full Text] [Related]
15. USP19 regulates DNA methylation damage repair and confers temozolomide resistance through MGMT stabilization. Liu J; Wang K; Zhu Q; Zhang Y; Chen Y; Lou Z; Yuan J CNS Neurosci Ther; 2024 Apr; 30(4):e14711. PubMed ID: 38644551 [TBL] [Abstract][Full Text] [Related]
16. Silencing SATB1 overcomes temozolomide resistance by downregulating MGMT expression and upregulating SLC22A18 expression in human glioblastoma cells. Yang B; Ma YB; Chu SH Cancer Gene Ther; 2018 Dec; 25(11-12):309-316. PubMed ID: 30140041 [TBL] [Abstract][Full Text] [Related]
17. MGMT genomic rearrangements contribute to chemotherapy resistance in gliomas. Oldrini B; Vaquero-Siguero N; Mu Q; Kroon P; Zhang Y; Galán-Ganga M; Bao Z; Wang Z; Liu H; Sa JK; Zhao J; Kim H; Rodriguez-Perales S; Nam DH; Verhaak RGW; Rabadan R; Jiang T; Wang J; Squatrito M Nat Commun; 2020 Aug; 11(1):3883. PubMed ID: 32753598 [TBL] [Abstract][Full Text] [Related]
18. Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. Agnihotri S; Gajadhar AS; Ternamian C; Gorlia T; Diefes KL; Mischel PS; Kelly J; McGown G; Thorncroft M; Carlson BL; Sarkaria JN; Margison GP; Aldape K; Hawkins C; Hegi M; Guha A J Clin Invest; 2012 Jan; 122(1):253-66. PubMed ID: 22156195 [TBL] [Abstract][Full Text] [Related]
19. Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas. Yin AA; He YL; Etcheverry A; Liu YH; Aubry M; Barnholtz-Sloan J; Liu BL; Mosser J; Lu ZF; Zhang X Clin Epigenetics; 2019 May; 11(1):76. PubMed ID: 31088577 [TBL] [Abstract][Full Text] [Related]
20. Glioblastoma Recurrence and the Role of O Storey K; Leder K; Hawkins-Daarud A; Swanson K; Ahmed AU; Rockne RC; Foo J JCO Clin Cancer Inform; 2019 Feb; 3():1-12. PubMed ID: 30758983 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]